Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

about

EMT induced by loss of LKB1 promotes migration and invasion of liver cancer cells through ZEB1-induced YAP signaling Mechanoregulation and pathology of YAP/TAZ via Hippo and non-Hippo mechanisms

P2860

Q58572592-A186B2C3-2716-4B6C-831D-1D6EF70024D5 Q58787445-C2ADC03A-AB45-474A-8D5D-C3D6C647DE0F

P2860

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

Item

http://www.wikidata.org/entity/Q47117055

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@en

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@nl

type

Item

label

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@en

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@nl

prefLabel

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@en

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@nl

P1476

Inhibition of YAP function ove ...... in melanoma cancer stem cells.

@en

P2093

Daniel Grun

http://www.w3.org/2001/XMLSchema#string

Gautam Adhikary

http://www.w3.org/2001/XMLSchema#string

Matthew L Fisher

http://www.w3.org/2001/XMLSchema#string

Richard L Eckert

http://www.w3.org/2001/XMLSchema#string

Wen Xu

http://www.w3.org/2001/XMLSchema#string

P2860

The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner

Relief of profound feedback inhibition of mitogenic signaling by RAF inhibitors attenuates their activity in BRAFV600E melanomas

Genetic and pharmacological disruption of the TEAD-YAP complex suppresses the oncogenic activity of YAP

The two faces of Hippo: targeting the Hippo pathway for regenerative medicine and cancer treatment

Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study

Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling.

Mutations of the BRAF gene in human cancer

Genetic variants in Hippo pathway genes YAP1, TEAD1 and TEAD4 are associated with melanoma-specific survival

Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial

Hippo signaling: growth control and beyond.

P304

110257-110272

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.22628

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-22T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29299145

http://www.w3.org/2001/XMLSchema#string

P932

5746380

http://www.w3.org/2001/XMLSchema#string

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

about

P2860

P2860

Inhibition of YAP function overcomes BRAF inhibitor resistance in melanoma cancer stem cells.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P577

P698

P932